Protein Degeneration Therapy Market Size & Share, by Application (Inflammatory, Neurology, Oncological, Respiratory); Route of Administration (Oral, Intravenous); Product Type (Degronimids, Immuno-modulatory Imide Drugs (IMiDs), Selective Androgen Receptor Degraders (SARD), Selective Estrogen Receptor Degraders (SERD), Specific Bromodomain and Extra-Terminal Motif (BET), DUB Inhibitors, PROTACs) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3968
  • Published Date: Feb 05, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Protein Degeneration Therapy Market size is poised to reach USD 169 Billion by the end of 2036, growing at a CAGR of 13% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of protein degeneration therapy was USD 125 Billion. The reason behind the growth is due to the growing burden of cancer across the globe which is one of the leading causes of death driven by smoking, and other significant factors. For instance, in 2040, there will be more than 29 million cases of cancer worldwide owing to population growth and aging. Moreover, targeted protein degradation has increased the number of druggable proteins available for use in cancer treatments and is a strategy to destroy cancer-causing proteins.

The growing advancements in protein degeneration therapy are believed to fuel protein degeneration therapy market growth. For instance, the successful endogenous protein degradation tool known as proteolysis targeting chimeric (PROTAC) technology was created in recent years which has demonstrated promising outcomes in clinical trials for the treatment of breast and prostate cancer.

Protein Degradation Therapy Market
Get more information on this report: Request Free Sample PDF

Protein Degeneration Therapy Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 125 Billion

Forecast Year Market Size (2036)

~ USD 169 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Protein Degeneration Therapy Market: Growth Drivers and Challenges


Growth Drivers

  • Growing Geriatric Population - The molecular etiology of several age-related disorders has been closely linked to degenerative protein changes or DPMs such as in age-related macular degeneration, or AMD which is one of the main causes of blindness in the globe. According to estimates, the proportion of the population aged 60 and up rose over 1 billion, and this figure is expected to increase by more than 2 billion by 2050.
  • Increasing Availability of Protein Degraders- Many degraders based on the PROTAC principle have already progressed to clinical testing which is being used in pharmaceuticals to selectively downregulate a target protein.
  • Protein Degeneration in Drug Delivery Systems- In the drug development process, the use of tiny compounds to cause targeted protein breakdown is rising, and the research on targeted protein degradation is also creating new avenues for the quickly expanding field of medication. Moreover, targeted protein degradation is gaining popularity because it is a relatively new method of drug development backed by growing clinical validation. For instance, the overall value of venture financing deals involving targeted protein degrader medicines (TPDs) increased by more than 1500% between 2017 and 2022.


  • Lack of Stability- Only a small range of concentration, temperature, ionic strength, and acidity conditions are stable for proteins and peptides therefore it is difficult to ensure the stability of protein formulations which is crucial as any alterations in protein integrity might lead to a reduction in therapeutic efficacy and can trigger immunogenic reactions in patients. Moreover, in the pharmaceutical industry, protein stability is especially important during the process of expression and purification.
  • Exorbitant Development Cost of Protein Degeneration Therapy Owing to the Complexity and Requirement of advanced technologies
  • Stringent rules and regulations can increase the overall time and cost which is expected to limit the introduction of new treatments

Protein Degeneration Therapy Segmentation

Route of Administration (Oral, Intravenous)

The oral segment in the protein degeneration therapy market is estimated to gain a robust revenue share of 60% in the coming years. Owing to its ease of use, non-invasive drug delivery methods have drawn a lot of attention in the field of biomedicine. Oral protein degeneration therapies are developed so that patients can take them conveniently and easily.

Oral administration improves convenience and patient compliance and offers a simple, non-invasive method that lessens patient discomfort. Oral administration makes it possible for medications to be released more gradually since for many protein degeneration treatments, careful dosage is necessary. Moreover, this route of administration also encourages scalability and cost-effectiveness, may be easily scaled up for mass production, and may become more widely accepted by providing them to a broader range of patients.

Application (Inflammatory, Neurology, Oncological, Respiratory)

The neurology segment in the protein degeneration therapy market is set to garner a notable share shortly. The number of neurological disorders-related deaths and disabilities is becoming more widely acknowledged as a global public health concern since more than 6 million people worldwide lose their lives to neurological illnesses each year. The need for efficient therapies is growing as neurological disorders are becoming more common. Moreover, recognized genetic pathways or substantial protein deposits that cause cell death are used to describe neurodegenerative diseases. The goal of protein degeneration therapy is to remove the aberrant protein deposits while also slowing down the disease and trying to specifically remove these harmful proteins.

Our in-depth analysis of the global protein degeneration therapy market includes the following segments:

     Product Type

  • Degronimids
  • Immuno-modulatory Imide Drugs (IMiDs,)
  •  Selective Androgen Receptor Degraders (SARD)
  • Selective Estrogen Receptor Degraders (SERD)
  •  Specific Bromodomain and Extra-Terminal Motif (BET)
  • DUB Inhibitors

     Route of Administration

  • Oral
  • Intravenous


  • Inflammatory
  •  Neurology
  •  Oncological
  •  Respiratory

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Protein Degeneration Therapy Industry - Regional Synopsis

North American Market Forecast

Protein degeneration therapy market in north America is predicted to account for the largest share of 35% by 2036 impelled by the rising spending in healthcare. For instance, in 2021, U.S. health spending climbed by over 2% to reach around USD 4 trillion. Particularly, 2022 saw a faster-than-expected 4% increase in healthcare spending in the United States. As a result, the market for therapeutic proteins has experienced unprecedented growth, and new approaches to treating diseases have been made possible by protein-based therapies in the region.

European Market Statistics

The Europe protein degeneration therapy market is estimated to be the second largest, during the forecast timeframe led by growing awareness about quality health. The European Union's actions have resulted in a heightened consciousness regarding the significance of optimal health and overall well-being, leading to the growing desire for personalized approaches to address several health-related concerns.

Research Nester
Protein Degradation Therapy Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Protein Degeneration Therapy Market

    • F. Hoffmann-La Roche AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • Amgen Inc.
    • Baxter International Inc.
    • Eli Lilly and Company
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • Sanofi SA


In The News

  • Amgen Inc. teamed up with Generate Biomedicines to identify and develop protein therapies for five targets, help multi-specific drug design even more, and create prospective lead compounds with predictable manufacturability and clinical behavior. In addition, by combining Amgen's biologics drug discovery expertise with Generate's AI platform, they can further shorten drug discovery timelines and could generate over USD 1 billion for the Flagship Pioneering spinout.
  • Eli Lilly and Company collaborated with Lycia Therapeutics, Inc. to address critical unmet medical needs in Lilly's therapeutic areas of focus, such as immunology and pain, and use cutting-edge new technology to tackle difficult illness areas such as immunology and pain. Further, this collaboration will enable the development of many therapeutic modalities, including antibodies and small compounds.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3968
  • Published Date: Feb 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing burden of cancer across the globe and the growing advancements in protein degenration therapy are the major factors driving the growth of the market.

The market size of protein degeneration therapy is anticipated to attain a CAGR of 13% over the forecast period, i.e., 2024-2036.

The major players in the market are Baxter International Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novo Nordisk A/S, Pfizer, Inc., and others.

The oral segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Protein Degeneration Therapy Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying